



Press release
Regulated information

Omega Pharma announces commencement of acceptance period for the takeover bid made by Couckinvest

Nazareth (Belgium) - 4 November 2011 (07:30 a.m. CET). Omega Pharma (OME BB, OMEP.BR), the specialist in over-the-counter medicines and healthcare products, announces that the acceptance period for the voluntary and conditional public takeover bid on Omega Pharma made by Couckinvest starts on 7 November 2011 and runs until and including 20 December 2011. Publication of the results of the bid is expected for 27 December 2011. Payment is scheduled for 10 January 2012.

As of today (4 November 2011), the prospectus (the offer document) and the acceptance forms will be available in electronic format on the website of Omega Pharma (www.omega-pharma.be). As of 7 November 2011, these documents will also be made available without any expense on the websites and at the desks of the paying agent banks (BNP Paribas Fortis, ING and Dexia).

The bid made by Couckinvest applies to all shares and warrants issued by Omega Pharma NV not yet owned by Couckinvest or Omega Pharma. The bid price is set at EUR 36.00 cash per share.

The bid price for warrants is different for each category of warrants:

Granting Date	Number of warrants outstanding	Bid price (EUR per warrant)
15 May 2003	5,275	15.52
16 December 2003	3,750	11.48
10 February 2005	21,788	0.26
10 February 2005	11,576	0.26
28 March 2006	8,000	0.01
5 February 2007	45,000	0.01
1 August 2008	3,800	10.34
1 August 2008	102,425	10.34
7 October 2009	28,500	9.01
31 December 2010	16,000	5.34
Total	246,114	

This table no longer takes into account the 28,050 warrants for which a notice of exercise was received and which will be converted later today (4 November 2011) into newly issued Omega Pharma shares.

This takeover bid is contingent upon the fulfilment of the following conditions: (i) that the bidding party will hold at least 90% of all shares in Omega Pharma as a result of this bid, (ii) that the required approval is obtained from the competent European competition authorities and (iii) that no events occur that have (or can reasonably be expected to have) a negative impact of more than 10% on the EBITDA of Omega Pharma and that the Bel-20 stock market index does not fall below 2,040.14 points. If the bidding party holds at least 95% of the shares outstanding of Omega Pharma following the bid, a squeeze-out bid at equal conditions will be launched. It is the intention to delist the Omega Pharma share from NYSE Euronext.

For more information, please contact

Chris Van Raemdonck (Chris.vanraemdonck@omega-pharma.be)

Investor Relations - Omega Pharma

Direct line: 0032 9 381 0331 - Cell: 0032 499 58 55 31